First time available for research use


Golimumab antibody from Simponi®

Therapeutic TNF-α-antibody from the original Simponi® commercial drug targeting the TNF-α-antigen, also referred to as Simponi® or golimumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Golimumab / Simponi

Product Reference

Drug nameSimponi®
API typeHuman IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology.
Pharmacotherapeutic group
Immunosuppressants, tumour necrosis factor alpha (TNF-α) inhibitors
ATC code
Target of antibody
TNF-α; Synonyms: DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF-α, which prevents the binding of TNF-α to its receptors.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The binding of human TNF by golimumab was shown to neutralise TNF-α-induced cell-surface expression of the adhesion molecules E-selectin, vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 by human endothelial cells. In vitro, TNF-induced secretion of interleukin (IL)-6, IL-8 and granulocyte-macrophage colony stimulating factor (GM-CSF) by human endothelial cells was also inhibited by golimumab.
Improvement in C-reactive protein (CRP) levels were observed relative to placebo groups and treatment with Simponi resulted in significant reductions from baseline in serum levels of IL-6, ICAM-1, matrix-metalloproteinase (MMP)-3 and vascular endothelial growth factor (VEGF) compared to control treatment. In addition, levels of TNF- were reduced in RA and AS patients and 15 levels of IL-8 were reduced in PsA patients. These changes were observed at the first assessment (week 4) after the initial Simponi administration and were generally maintained through week 24.
Original license holder
Marketing authorisation numbers
EU/1/09/546/001 - 008
Marketing authorisation holder
Janssen Biologics B.V.
Einsteinweg 101
2333 CB Leiden
The Netherlands
Name of the manufacturer of the biological active substance
Janssen BiologicsB.V. Einsteinweg 101
NL-2333 CB Leiden
The Netherlands

Janssen Biologics (Ireland)
Co. Cork
Name and address of the manufacturer(s) responsible for batch releaseJanssen Biologics B.V.
Einsteinweg 101
NL-2333 CB Leiden
The Netherlands
Max shelf life
18 months
Storage conditions
2°C – 8°C
List of excipients
L-histidine monohydrochloride monohydrate
Polysorbate 80
Water for injection